Implementability of opioid deprescribing interventions at transitions of care: A scoping review

IF 3.1 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Jeffery Wang, Carl R. Schneider, Aili V. Langford, Mouna Sawan, Chung-Wei Christine Lin, Antonius Nugraha Widhi Pratama, Danijela Gnjidic
{"title":"Implementability of opioid deprescribing interventions at transitions of care: A scoping review","authors":"Jeffery Wang,&nbsp;Carl R. Schneider,&nbsp;Aili V. Langford,&nbsp;Mouna Sawan,&nbsp;Chung-Wei Christine Lin,&nbsp;Antonius Nugraha Widhi Pratama,&nbsp;Danijela Gnjidic","doi":"10.1111/bcp.16369","DOIUrl":null,"url":null,"abstract":"<p>Continuation of opioids at transitions of care increases the risk of long-term opioid use and related harm. To our knowledge, no study has examined the implementability of opioid deprescribing interventions at transitions of care. Our scoping review aimed to identify the type of opioid deprescribing interventions employed at transitions of care and assess the implementability of tested interventions. Nine electronic databases were searched on 15 May 2023 for English-language studies of adults transitioning between care settings, where opioid deprescribing interventions targeting patients, clinicians or health systems were implemented. Implementability was assessed using the Cochrane Intervention Complexity Assessment Tool for Systematic Reviews to determine intervention complexity, and mapped to the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework to understand the process evaluation. A total of 79 studies were identified, with 94.0% (<i>n =</i> 74) examining hospital-to-home transitions. Mixed interventions (combination of pharmacological and nonpharmacological) were tested in 49.0% (<i>n =</i> 39) of studies. Pharmacological interventions were identified in 31.0% (<i>n =</i> 24) of studies, and the remaining 20.0% (<i>n =</i> 16) applied nonpharmacological interventions. Mixed interventions comprising multiple components were the most complex and resulted in reduced opioid use across transitions of care in 28.0% (<i>n =</i> 22) of studies. Few studies reported on RE-AIM dimensions including implementation (5.0% of studies), reach (4.0%), adoption (4.0%) and maintenance (0%). Most opioid deprescribing interventions targeted hospital to home care transition with mixed results in opioid deprescribing. Further research should consider the implementability of interventions during transitions of care to elucidate the impact of opioid deprescribing interventions across care settings.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":"91 3","pages":"698-728"},"PeriodicalIF":3.1000,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcp.16369","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Continuation of opioids at transitions of care increases the risk of long-term opioid use and related harm. To our knowledge, no study has examined the implementability of opioid deprescribing interventions at transitions of care. Our scoping review aimed to identify the type of opioid deprescribing interventions employed at transitions of care and assess the implementability of tested interventions. Nine electronic databases were searched on 15 May 2023 for English-language studies of adults transitioning between care settings, where opioid deprescribing interventions targeting patients, clinicians or health systems were implemented. Implementability was assessed using the Cochrane Intervention Complexity Assessment Tool for Systematic Reviews to determine intervention complexity, and mapped to the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework to understand the process evaluation. A total of 79 studies were identified, with 94.0% (n = 74) examining hospital-to-home transitions. Mixed interventions (combination of pharmacological and nonpharmacological) were tested in 49.0% (n = 39) of studies. Pharmacological interventions were identified in 31.0% (n = 24) of studies, and the remaining 20.0% (n = 16) applied nonpharmacological interventions. Mixed interventions comprising multiple components were the most complex and resulted in reduced opioid use across transitions of care in 28.0% (n = 22) of studies. Few studies reported on RE-AIM dimensions including implementation (5.0% of studies), reach (4.0%), adoption (4.0%) and maintenance (0%). Most opioid deprescribing interventions targeted hospital to home care transition with mixed results in opioid deprescribing. Further research should consider the implementability of interventions during transitions of care to elucidate the impact of opioid deprescribing interventions across care settings.

阿片类药物处方干预措施在护理过渡阶段的可实施性:范围审查。
在护理过渡期间继续使用阿片类药物会增加长期使用阿片类药物和相关危害的风险。据我们所知,没有研究检查过阿片类药物处方干预措施在护理过渡阶段的可实施性。我们的范围审查旨在确定在护理过渡中使用的阿片类药物处方干预措施的类型,并评估测试干预措施的可实施性。2023年5月15日,对9个电子数据库进行了检索,以获取在针对患者、临床医生或卫生系统实施阿片类药物处方干预措施的护理机构之间过渡的成年人的英语研究。可实施性评估使用Cochrane干预复杂性评估工具进行系统评价,以确定干预的复杂性,并映射到Reach,有效性,采用,实施,维护(RE-AIM)框架,以了解过程评估。共有79项研究被确定,其中94.0% (n = 74)研究了从医院到家庭的转变。49.0% (n = 39)的研究测试了混合干预措施(药物和非药物联合)。31.0% (n = 24)的研究采用了药物干预,其余20.0% (n = 16)采用了非药物干预。由多种成分组成的混合干预措施是最复杂的,在28.0% (n = 22)的研究中,阿片类药物的使用在护理过渡期间减少了。很少有研究报告了RE-AIM的维度,包括实施(5.0%的研究)、达到(4.0%)、采用(4.0%)和维护(0%)。大多数阿片类药物处方减少干预措施的目标是医院到家庭护理过渡,阿片类药物处方减少的结果好坏参半。进一步的研究应考虑在护理过渡期间干预措施的可实施性,以阐明阿片类药物处方干预措施对整个护理环境的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
8.80%
发文量
419
审稿时长
1 months
期刊介绍: Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信